School of Medicine Gets $20 Million From the Permanent University Funds

Translate to Spanish or other 102 languages!

- Advertisement -

Mega Doctor News

Dr. John Krouse
Dr. John Krouse

The University of Texas Rio Grande Valley School of Medicine in Edinburg. The University of Texas System Board of RegentsĀ reinforced its commitment to The UTRGV School of Medicine, which has a major campus in Edinburg, by approving $20 million in Permanent University Funds (PUF) for capital expenses. ā€œWe are grateful to the Board of Regents for its continued support of the UTRGV School of Medicine,ā€ said Dr. John Krouse, Dean of the UTRGV School of Medicine and Vice president for Health Affairs.Ā ā€œThis allocation will enable the School of Medicine to become a leader in research that will benefit the Rio Grande Valley and beyond, and prepare the next generation of physicians who will provide exceptional care to the communities they serve.ā€

The Edinburg Mayor and Edinburg City Council, along with the Edinburg Economic Development Corporation and its Board of Directors, lobby the Texas Legislature and the UT System Board of Regents on matters that benefit and protect UTRGV and its School of Medicine, which have major campuses in the city. Building Photo by Silver Salas\. Dr. Krouse photo by Roberto Hugo Gonzalez.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual ā€œFishing for Hopeā€ Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.Ā 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and PreventionĀ (CDC), making it one of the nation's leading causes of death.
- Advertisement -